Mersana Therapeutics (MRSN)
(Real Time Quote from BATS)
$3.20 USD
+0.04 (1.27%)
Updated Apr 30, 2024 01:48 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Mersana Therapeutics, Inc. [MRSN]
Reports for Purchase
Showing records 101 - 120 ( 197 total )
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
XMT-1536 Activity Exceeds Expectations; Target Raised to $26
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
XMT-1536 Expansion Impresses: Broad, Deep and Deepening Responses in PROC
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
One Becomes Two, 1592 Joins 1536 in the Clinic
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASCO Beckons; But the 2H20 Update Likely More Important
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Financials; Interim XMT-1536 Expansion Data Coming Soon at ASCO
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Impact on Coverage Universe: Week of April 20 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Impact on Coverage Universe: Week of March 30 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Impact on Coverage Universe: Week of March 30 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Dose Escalation; Next Up Expansion Data and Registration Study
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Responses and Correlation With H-Score In Line With Expectations.
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D